Adipotide vs AOD-9604

Adipotide is a peptidomimetic that homes to blood vessels supplying white fat and triggers their death; AOD-9604 is a modified fragment of growth hormone. Neither is approved.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

🧪

Adipotide

A peptidomimetic that targets prohibitin on the blood vessels of white fat and triggers their apoptosis, studied in obese monkeys.

BEST STUDIED FOR

Incretin & metabolic

Read the cited profile →

🧪

	Adipotide	AOD-9604
The key difference	Targets fat-tissue blood vessels	GH fragment acting on fat metabolism
Class	Incretin & metabolic	Incretin & metabolic
Mechanism	Adipotide pairs a fat-vasculature homing motif with a pro-apoptotic sequence; cutting off the blood supply of white adipose tissue reduced fat mass in animals.	The 177–191 region of GH is associated with lipolytic activity.
Status	Primate study published in 2011; no human efficacy trials reported.	Reached phase 2 obesity trials in the early 2000s; not approved as a medicine. Also studied in an animal osteoarthritis model.
Reported safety signals	Published data are limited to animal work; there is no human safety data.	Development-era trials reported it as tolerated; it is detected in anti-doping testing. Human efficacy for weight was not established.
A key study	In obese monkeys, adipotide caused weight loss and improved insulin resistance by targeting white-fat vasculature. (Sci Transl Med 2011, PMID 22072637)	In obese mice, chronic AOD9604 increased fat oxidation and reduced body weight, and the effect was not mediated by the GH receptor. (Int J Obes Relat Metab Disord 2001, PMID 11673763)

Adipotide is a vascular-targeting concept with primate data only; AOD-9604 a metabolic fragment with negative human trials. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Adipotide] A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys — Sci Transl Med 2011. PMID 22072637
[Adipotide] Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys" — Sci Transl Med 2012. PMID 22539771
[Adipotide] A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication — J Control Release 2013. PMID 23871959
[AOD-9604] Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment — Int J Obes Relat Metab Disord 2001. PMID 11673763
[AOD-9604] Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide — Biochem Mol Biol Int 1994. PMID 7987248
[AOD-9604] Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model — Ann Clin Lab Sci 2015. PMID 26275694

FREQUENTLY ASKED

What is the difference between Adipotide and AOD-9604?

Adipotide is a peptidomimetic that homes to blood vessels supplying white fat and triggers their death; AOD-9604 is a modified fragment of growth hormone. Neither is approved.

What is the regulatory status of Adipotide and AOD-9604?

Adipotide: Primate study published in 2011; no human efficacy trials reported. AOD-9604: Reached phase 2 obesity trials in the early 2000s; not approved as a medicine. Also studied in an animal osteoarthritis model.

What safety signals have been reported?

Adipotide: Published data are limited to animal work; there is no human safety data. AOD-9604: Development-era trials reported it as tolerated; it is detected in anti-doping testing. Human efficacy for weight was not established.

Which studies is this comparison based on?

For Adipotide: “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys” (PMID 22072637); “Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys"” (PMID 22539771); “A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication” (PMID 23871959). For AOD-9604: “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment” (PMID 11673763); “Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide” (PMID 7987248); “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model” (PMID 26275694).